undergo Sea Changes

Scientific Advisory Board to undergo Sea Changes; Thanks to severity of Alzheimer’s Disease!


Synaptogenix, on July 26, 2022, did announce that it had made alterations to its SAB (Scientific Advisory Board) with regards to preparing for Phase 2 data, that too, from its Phase 2b clinical trial of Bryostatin-1 for those contracting moderately severe and advanced AD (Alzheimer’s Disease).

SAB constitutes academic and industry leaders in drug development and is looked upon as being instrumental in developing Synaptogenix’s regenerative therapies for MS (multiple sclerosis), fragile X syndrome, and AD.

Dr. George Perry would be chairing SAB, accompanied by Dr. Paul Coleman, Dr. Zaven Khachaturian, and Prof. Robert Howard. Dr. Alan Tuchman, the CEO, expressed his pleasure over the same.

The line of expertise of these stalwarts includes molecular mechanisms of neuro regeneration and degeneration, AD therapeutics’ clinical trials, and interactive biochemical pathways of getting old, neuronal loss, and synaptic loss.

As a gentle reminder, Synaptogenix would be holding a corporate update conference call at 4:30 p.m. ET. Dr. Alan Tuchman (the CEO, as mentioned above), along with Dr. Daniel Alkon would be hosting it. They would also be holding live Q&A after their prepared remarks.

The US toll-free dial-in to have conference call is (877) 407-8293. International dial-in number comes across as 1-(201) 689-8349.

Dr. George Perry

He is, at present, the founding editor-in-chief for the “Journal of Alzheimer’s Disease” (an international multidisciplinary journal specializing in Alzheimer’s disease. He has specialized in Alzheimer’s cytopathology and the pathophysiological consequences.

Dr. Marwan Sabbagh

He has published more than 400 medical and scientific research articles on Alzheimer’s and stays one of the prominent investigators as well as opinion leaders in the nationally recognized Alzheimer’s treatment trials. At present, he is professor of neurology in the Alzheimer’s and Memory Disorders Division at the Barrow Neurological Institute in Phoenix, Arizona.

Dr. Paul Coleman

He has served for years as a “Full Professor” at the University of Rochester School of Medicine. It was at that time that he served as Director of the University of Rochester Medical Center Alzheimer’s Disease Center along with being the Director of an NIH Training Program in Neurobiology of Aging. His area of interest is differentiation of changes in brain while fighting Alzheimer’s disease, right from changes related to non-demented, normal aging. Of late, he has expanded his interests in epigenetics as well. The accolades in his name include a Leadership and Excellence in Alzheimer’s Disease Award by the National Institutes of Health and a Pioneer Award from the National Alzheimer’s Association.

Prof. Robert Howard

He serves as a professor of Old Age Psychiatry at the University College London and Mental Health Lead of the University College London Hospitals’ Biomedical Research Centre. He is into investigating the mental health symptoms in geriatric population and psychological therapy approaches regarding the same.

Dr. Zaven Khachaturian

He is presiding over the Campaign to Prevent Alzheimer Disease (PAD2020.org) and also serves as the associate director, Neuroscience & Neuropsychology of Aging Program at the National Institution on Aging NIA/NIH.

It’s an entirely “Wait & Watch” situation regarding the SAB!

Leave a Reply

Your email address will not be published.